Spot on Biotechnology Business - BIO.NRW

BIO.NRW health and medicine
The Bayer Group is a global enterprise with
core competencies in the fields of health
care, nutrition and high-tech materials.
Bayer HealthCare, a subgroup of Bayer
AG with annual sales of EUR 16.913 billion
(2010), is one of the world’s leading, innovative
companies in the healthcare and
medical products industry and is based
in Leverkusen, Germany. The company
combines the global activities of the Animal
Biocheck introduced Polycheck ® Platform
Technology as a tool for medical differential
diagnosis. The multiparameter test device
enables a serological quantitative allergy
screening on the basis of solid phase Immuno-Assay-Technology
using monoclonal
antibody detection; color-coded devices are
presenting different allergen panels.
For autoimmune diagnosis a quantitative
screening for disease patterns is new
Biofrontera is a biopharmaceutical company
which specializes in the development
and distribution of medical products and
cosmeceuticals for the care and treatment
of dermatological diseases.The cosmeceutical
product Belixos is a creme for the basic
care of inflamed, itchy and flaky skin, currently
marketed in Germany and the MENA
region. Biofronteras leading prescription
Health, Consumer Care, Medical Care and
Pharmaceuticals divisions.
Bayer HealthCare’s aim is to discover and
manufacture products that will improve human
and animal health worldwide.
Bayer HealthCare has a global workforce
of 55,700 employees (Dec 31, 2010) and is
represented in more than 100 countries.
family member of Polycheck ® . Quantitative
evaluation is performed by picture scanning
and calculation by Biocheck Imaging
Software.
The assay prodedure can be worked
out manually or fully automated including
matching with central Laboratory Information
Systems (LIS).
drug BF-200 ALA has demonstrated excellent
efficacy and safety and superiority over
its competitors in Phase III trials for actinic
keratosis. It is now in the centralized European
approval process, and EU wide approval
is anticipated for Q4 2011. BF-derm1 is in
clinical Phase II for chronic, antihistaminerefractory
urticaria. Preclinical and clinical
phase IIa trials have already demonstrated
the efficacy and excellent safety profile
of this product. First tests in humans of
BF-1, a new drug for migraine prophylaxis,
demonstrated excellent pharmacological
properties of the drug.
Name
Postal Code/City
Fon
Internet
Name
Address
Postal Code/City
Fon
Fax
Email
Internet
Employees
Founded (year)
Name
Address
Postal Code/City
Fon
Fax
Email
Internet
Employees
Founded (year)
Bayer HealthCare AG
51368 Leverkusen
+49-214-300
www.bayerhealthcare.com
BioCheck GmbH
Vorbergweg 41
48159 Muenster
+49-251-2150-868
+49-251-2150-870
office@polycheck.de
www.biocheck.de
14
1999
Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
+49-214-87632-22
+49-214-87632-90
press@biofrontera.com
www.biofrontera.com
27
1997
35